 |
|
COMMENTS AND OPINIONS
Radiotherapy Dose in the Treatment of Localized Prostate Cancer
Karl Mikael Kälkner, MD, PhD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Merglen et al1 suggested that radical prostatectomy provides the best chance of long-term survival. The authors performed a population-based cohort study including 844 patients with localized prostate cancer. Comparing different treatment methods outside of randomized trials is always affected by selection bias. It is well known that patients receiving radiotherapy are older and have more advanced tumor stages and higher comorbidity. The analysis of prostate-specific survival was elegantly adjusted for several prognostic factors.
However, no information was reported regarding delivered doses to the target during radiotherapy. The dose is an important prognostic factor. A dose-response relationship has been reported in a dose escalation trial2 and in randomized trials.3-4 In a trial randomizing 669 patients, the risk of failure was reduced from 64% to 54% at 5 years when the dose was increased from 68 Gy to 78 Gy (to convert to rads, multiply by 100).3 . . . [Full Text of this Article]
AUTHOR INFORMATION
RELATED ARTICLE
Short- and Long-term Mortality With Localized Prostate Cancer
Arnaud Merglen, Franz Schmidlin, Gerald Fioretta, Helena M. Verkooijen, Elisabetta Rapiti, Roberto Zanetti, Raymond Miralbell, and Christine Bouchardy
Arch Intern Med. 2007;167(18):1944-1950.
ABSTRACT
| FULL TEXT
RELATED LETTER
Radiotherapy Dose in the Treatment of Localized Prostate Cancer—Reply
Elisabetta Rapiti, Arnaud Merglen, and Christine Bouchardy
Arch Intern Med. 2008;168(12):1353.
EXTRACT
| FULL TEXT
|
